PresentationSofia HeigisChief Executive Officer Good morning, everyone, and thank you for joining us for this update on our Q4 sales and strategic outlook. My name is Sofia Heigis, CEO of Oncopeptides. I am today joined by our CFO, Henrik Bergentoft, and we will walk you through the numbers, the context behind them and our updated path forward. This is what we announced yesterday, and I will address all these points this morning. Let's go to the numbers. For the fourth quarter of 2025, we achieved net sale ...